Robert Leo Murphy

Grants

Grants per year 1997 2027

• 34 Active
• 80 Finished

Grants per year

Search results

• Finished

  International Development if a Health-Related Quality of Life Measure Specific to HIV/AIDS: Identification of Appropriate Domains, Creation of an Item Bank, Cultural Adaptation and Psychosometric Validations

  Murphy, R. L.

  Assistance Publique-Hôpitaux de Paris

  8/1/07 → 9/30/08

  Project: Research project

• Enhancement of Retrovirology and Tuberculosis Laboratory Capabilities in Mali

  Murphy, R. L.

  National Institute of Allergy and Infectious Diseases

  2/1/07 → 11/30/13

  Project: Research project

• Units for HIV/AIDS Clinical Trials Networks (Northwestern University Clinical Trial Unit)

  Murphy, R. L., Palella Jr, F. J., Palella Jr, F. J., Cohen, B. A., Achenbach, C. J., Green, R., Green, R., Flaherty, J. P., Flaherty, J. P., Sutton, S. H., Taiwo, B. O., Taiwo, B. O., Taiwo, B. O. & Cohn, S. E.

  National Institute of Allergy and Infectious Diseases

  2/1/07 → 11/30/13

  Project: Research project

• AIDS Clinical Trials Group Network ("ACTG")

  Murphy, R. L.

  Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases

  1/1/07 → 5/31/11

  Project: Research project

• AIDS Clinical Trials Group ACTG

  Murphy, R. L.

  Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases

  6/1/06 → 5/31/13

  Project: Research project

• Directly Observed, Community-Based Treatment in Nigeria

  Murphy, R. L. & Taiwo, B. O.

  Doris Duke Charitable Foundation

  1/1/06 → 6/30/08

  Project: Research project

• A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination with D4T and 3TC in 2NN Patients

  Murphy, R. L.

  Boehringer Ingelheim Pharmaceuticals, Inc., International Antiviral Therapy Evaluation Center B.V.

  10/10/05 → 5/31/06

  Project: Research project

• Prot# TMC125-C229: An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks

  Murphy, R. L.

  PPD Development, Tibotec Pharmaceuticals Ltd.

  9/7/05 → 8/12/08

  Project: Research project

• PROsIT: A Total Patient-Reported Outcomes Solution

  Murphy, R. L. & Flaherty, J. P.

  BrightOutcome Inc., National Institute of Mental Health

  7/19/05 → 7/18/08

  Project: Research project

  • Patient Reported Outcome Measures
  • HIV
  • Tongue
  • Patient Outcome Assessment
  • Tablets

• Nanoemulsions as Adjuvants for Nasal-Spray Vaccines

  Murphy, R. L.

  University of Michigan, Bill & Melinda Gates Foundation

  7/1/05 → 6/30/09

  Project: Research project

• Prot# A4001026: A Mltcntr, Rndmzd, Dbl-Blind, Comparative Trial Of a Novel CCR5 Antagonist, UK-427,857, in Combination w/Zidovudine/Lamivudine v. Efavirenz in Combination w/Zidovudine/Lamivudine for the Treatment of Antiretroviral-Naïve HIV-1 Infected Sbj

  Murphy, R. L.

  Quintiles, Inc., Pfizer Inc.

  6/6/05 → 8/8/07

  Project: Research project

• Prot# TMC114-C215: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-Experienced Subjects

  Murphy, R. L.

  Medisearch International Corp., Tibotec Pharmaceuticals Ltd.

  3/31/05 → 9/2/08

  Project: Research project

• Prot# AI424-075: The SABAR Study: Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen

  Murphy, R. L.

  Bristol-Myers Squibb Company

  2/15/05 → 10/22/10

  Project: Research project

• Prot# MANON 02: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of Two Schedules of an Homologous Prime-Boost with the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

  Murphy, R. L.

  ORVACS

  11/29/04 → 12/31/07

  Project: Research project

• Prot# INCB 8721 RVT-203: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, & Virological Effect of 50, 100, & 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Co

  Murphy, R. L.

  Quintiles, Inc., Incyte Corporation

  9/8/04 → 4/13/07

  Project: Research project

• Prot# TMC125-C223: A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125, in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations

  Murphy, R. L.

  PPD Development, Tibotec Pharmaceuticals Ltd.

  7/20/04 → 8/8/07

  Project: Research project

• Prot# SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

  Murphy, R. L.

  Abbott Laboratories

  4/4/04 → 11/4/06

  Project: Research project

• Rapid Expansion of Antiretroviral Therapy Programs (PEPFAR)

  Murphy, R. L. & Taiwo, B. O.

  Harvard University, Health Resources and Services Administration

  3/1/04 → 2/28/09

  Project: Research project

• CIPRA

  Murphy, R. L.

  Harvard University, National Institute of Allergy and Infectious Diseases

  3/1/04 → 2/28/06

  Project: Research project

• Prot# Tibotec TMC114-C202: A Phase II Randomized, Controlled, Partially Blinded, 48-Week Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced, Multi PI-Experienced HIV-1 Infected Subjects

  Murphy, R. L.

  Inveresk Research, Inc., Tibotec Pharmaceuticals Ltd.

  2/9/04 → 8/12/08

  Project: Research project

• Northwestern Adult AIDS Clinical Trials Unit

  Murphy, R. L.

  National Institute of Allergy and Infectious Diseases

  1/1/04 → 12/31/07

  Project: Research project

• Regional Center for Excellence for Bioterrorism: Molecular Analysis and Intervention: Emergency Response Plan Component

  Wolinsky, S. M., Murphy, R. L., Stosor, V., Zembower, T. R. & Zembower, T. R.

  University of Chicago, National Institute of Allergy and Infectious Diseases

  9/4/03 → 2/28/09

  Project: Research project

• Prot# SILCAAT: A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy (the "SILCAAT Trial")

  Murphy, R. L.

  University of Minnesota, Chiron Corporation

  2/18/03 → 12/31/08

  Project: Research project

• Northwestern Adult AIDS Clinical Trials Unit

  Wolinsky, S. M., Wolinsky, S. M., Lowe Jr, W. L., Lowe Jr, W. L., Phair, J. P., Phair, J. P., Garcia, P. M., Garcia, P. M., Murphy, R. L., Palella Jr, F. J., Palella Jr, F. J., Hirschtick, R. E., Hirschtick, R. E., Pelzer, H. J., Pelzer, H. J., Cohen, B. A., Cohen, B. A., Hoff, F. L. & Sutton, S. H.

  National Institute of Allergy and Infectious Diseases

  1/1/00 → 12/31/07

  Project: Research project

• Study of the Ocular Complications of AIDS (SOCA)

  Jampol, L. M., Murphy, R. L. & Lyon, A.

  Johns Hopkins University, Kennedy Institute - National Eye Clinic

  8/1/98 → 7/31/10

  Project: Research project